ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - Cover2

When small companies have big ideas that could benefit countless patients, they must find
partners to expand the spectrum of their expertise and infrastructure to help them test these
ideas and facilitate their speedy translation to therapeutics. The key driver in this process is the
need of patients who are quickly running out of time, and the prime considerations for both
parent and partnering companies are efficacy and safety of the therapeutic.
Here we have the CSO and director of research of a startup biotech company, Paros Bio, and
experts from their partnering contract research organization (CRO), Charles River, discussing
the specifics of their work and productive partnership. Paros Bio, driven by their mission of
bringing a novel gene therapy to young patients suffering from a devastating form of Alzheimer's
disease (AD), must balance scientific rigor and expense, when seeking a worthy partner.
On the other hand, Charles River, committed to their client's mission, must continue to enhance
and retain their range of expertise while understanding and meeting the specific needs of diverse
projects. This discussion focuses on the emergence of Paros Bio, the science behind their PSEN1
program for Autosomal Dominant Alzheimer's Disease (ADAD), and the perspectives from
experts at both companies on the nature of their work and alliance.
Beyond key lessons that can be gleaned from a history of the disease, and the challenges of
developing novel therapeutic strategies in the wake of others that have failed, this expert panel
discussion provides a glimpse into the intricacies of developing communication and trust among
scattered stakeholders and the ability to prioritize scientific rigor, time, and cost in the face of
inevitable setbacks in the practice of cutting-edge science.
2 |
© GEN Publishing, August 2022
Cover Image: Lars Neumann/Getty Images


Table of Contents for the Digital Edition of ChasRiver_Aug2022_Perspectives-Toward-a-Treatment

ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - Cover1
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - Cover2
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - 3
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - 4
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - 5
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - 6
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - 7
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - 8
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - 9
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - 10
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - 11
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - 12
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - 13
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - 14
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - Cover3
ChasRiver_Aug2022_Perspectives-Toward-a-Treatment - Cover4